Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EPAD

- PMLiVE

Teva backs UK’s dementia drive with $21m investment

Pharma company will support National Institute for Health Research

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

EU flag

Pharma wants review of EMA pharmacovigilance fees

EFPIA among associations to call for ‘balanced and transparent’ funding

- PMLiVE

EFPIA looks to Lilly for head of comms

Pharma trade body hires Liam English

- PMLiVE

Pharma clinical data sharing policy comes into effect

GSK and Sanofi among companies to announce public support of new guidelines

- PMLiVE

G8 sets 2025 target for effective dementia treatment

World leaders pledge more research funding

- PMLiVE

Merck takes Alzheimer’s hope into phase III

MK-8931 moves to late-stage study after positive early data

- PMLiVE

IMI launches dementia trials alliance

EU group wants to revamp approach to Alzheimer’s research

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

- PMLiVE

Dementia map reveals extent of under-diagnosis

Less than half of patients in England are diagnosed

EU flag

EFPIA: Disclose payments or face legislation

European pharma industry needs to get behind self-regulated transparency

- PMLiVE

FDA approves Alzheimer’s diagnostic drug

GE Healthcare's Vizamyl to compete with Lilly's Amyvid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links